Abstract
Early detection of pancreatic cancer has been a long-standing challenge in determining prognosis and management of the deadly disease. Although the incidence of pancreatic cancer is low (2% of all malignancies), it is the fourth leading cause of deaths attributable to cancer in the U.S. A major cause for the high mortality rate, which exceeds 85%, is the difficulty in diagnosing the disease early in its development. The relative lack of reliable diagnostic tools to screen patients who are asymptomatic prior to the aggressive progression of disease has been the primary contributing factor in the high mortality rate in this patient population. Indeed, 80-90% of patients with pancreatic cancer have relatively small unresectable tumors at the time of diagnosis. Therefore, there is an unmet need for a highly sensitive diagnostic imaging modality to detect early-stage pancreatic cancer, as this may save the lives of many thousands of patients. Many literature reviews have been published on various aspects of pancreatic cancer, including biology, screening, and therapy; however, limited information is available on early detection, especially the use of highly sensitive modalities such as positron emission tomography (PET). Current [18F]FDG/PET imaging combined with CT (PET/CT) lacks the necessary sensitivity and specificity for detection of small lesions (~2-3 mm) of pancreatic cancer that may be resectable and curable. Furthermore, accumulation of [18F]FDG in inflammatory tissue is a major problem; therefore, an appropriate PET tracer that is both highly sensitive and specific for carcinoma is necessary for PET imaging of early stage pancreatic cancer. This review focuses on early detection of pancreatic cancer by PET, including new targets and the development and application of new PET tracers.
Keywords: [18F]-lactose, HIP/PAP, molecular imaging, PDAC, PET.
Current Medicinal Chemistry
Title:Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes
Volume: 22 Issue: 29
Author(s): Mian M. Alauddin and Louis De Palatis
Affiliation:
Keywords: [18F]-lactose, HIP/PAP, molecular imaging, PDAC, PET.
Abstract: Early detection of pancreatic cancer has been a long-standing challenge in determining prognosis and management of the deadly disease. Although the incidence of pancreatic cancer is low (2% of all malignancies), it is the fourth leading cause of deaths attributable to cancer in the U.S. A major cause for the high mortality rate, which exceeds 85%, is the difficulty in diagnosing the disease early in its development. The relative lack of reliable diagnostic tools to screen patients who are asymptomatic prior to the aggressive progression of disease has been the primary contributing factor in the high mortality rate in this patient population. Indeed, 80-90% of patients with pancreatic cancer have relatively small unresectable tumors at the time of diagnosis. Therefore, there is an unmet need for a highly sensitive diagnostic imaging modality to detect early-stage pancreatic cancer, as this may save the lives of many thousands of patients. Many literature reviews have been published on various aspects of pancreatic cancer, including biology, screening, and therapy; however, limited information is available on early detection, especially the use of highly sensitive modalities such as positron emission tomography (PET). Current [18F]FDG/PET imaging combined with CT (PET/CT) lacks the necessary sensitivity and specificity for detection of small lesions (~2-3 mm) of pancreatic cancer that may be resectable and curable. Furthermore, accumulation of [18F]FDG in inflammatory tissue is a major problem; therefore, an appropriate PET tracer that is both highly sensitive and specific for carcinoma is necessary for PET imaging of early stage pancreatic cancer. This review focuses on early detection of pancreatic cancer by PET, including new targets and the development and application of new PET tracers.
Export Options
About this article
Cite this article as:
Alauddin M. Mian and De Palatis Louis, Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes, Current Medicinal Chemistry 2015; 22 (29) . https://dx.doi.org/10.2174/0929867322666150821094015
DOI https://dx.doi.org/10.2174/0929867322666150821094015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design In Silico Identification of Natural Lead Molecules from the Genus of Phyllanthus Against Hepatitis B Virus Reverse Transcriptase
The Natural Products Journal Protein Biomarkers in Cancers of the Digestive Tract - a Step Towards Personalized Medicine
Current Proteomics Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Prevention and Treatment of Bone Metastases
Current Pharmaceutical Design Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Translational Research of Optical Molecular Imaging for Personalized Medicine
Current Molecular Medicine Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Polymeric Carrier Systems for siRNA Delivery
Current Topics in Medicinal Chemistry The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry 4-Oxothiazolidines with Exocyclic C=C Double Bond(s): Synthesis, Structure, Reactions and Biological Activity
Current Organic Chemistry